8-K: BD (Becton, Dickinson and Company) Announces Strong Q1 Fiscal 2025 Results and Plans to Separate Biosciences and Diagnostic Solutions Business

Becton, Dickinson and Company (BD) reports better-than-expected Q1 fiscal 2025 results and unveils plans to separate its Biosciences and Diagnostic Solutions business to unlock value and enhance strategic focus.

Summary

• BD reported strong Q1 fiscal 2025 results, exceeding expectations for revenue, margin, and earnings per share.
• Revenue increased by 9.8% to $5.2 billion as reported, with organic revenue growth of 3.9%.
• GAAP diluted EPS grew by 8.3% to $1.04, while adjusted diluted EPS increased by 28.0% to $3.43.
• The company has increased its FY25 adjusted diluted EPS guidance at the midpoint.
• BD's board has authorized management to pursue a plan to separate the Biosciences and Diagnostic Solutions business.
• The separation is expected to unlock value by creating a more focused MedTech leader (New BD) and a differentiated Life Sciences Tools and Diagnostics company.
• New BD is expected to have fiscal 2024 revenue of approximately $17.8 billion, with a $70+ billion addressable market growing at approximately 5%.
• Biosciences and Diagnostic Solutions is expected to have approximately $3.4 billion in fiscal 2024 revenue with a $22+ billion addressable market growing at midto high-single-digits.
• The company expects to announce more specifics on the separation plans by the end of fiscal 2025 and intends to target completion of the transaction in fiscal 2026.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong Q1 results and a strategic plan to unlock further value through the separation of a business segment. The increased EPS guidance and share repurchase program further contribute to the positive sentiment.

Positives

• Strong Q1 fiscal 2025 financial performance with revenue, margin, and EPS exceeding expectations.
• Increased FY25 adjusted diluted EPS guidance.
• Planned separation of Biosciences and Diagnostic Solutions to unlock value and enhance strategic focus.
• Share repurchase program demonstrating confidence in the company's future.
• Growth in key segments such as BD Medical, driven by Medication Delivery Solutions and Medication Management Solutions.
• Expansion of innovative fingertip blood testing for use by U.S. health systems.
• BD Onclarity HPV Assay added to ASCCP guidelines and used in cervical cancer screening study.

Negatives

• PS (Pharmaceutical Systems) performance reflects timing in Biologics and transitory market dynamics that resulted in lower demand for prefillable syringes.
• BDB (Biosciences) performance reflects transitory market dynamics that resulted in lower demand for research solutions in China and the U.S. as expected.
• MMS (Medication Management Solutions) performance reflects double-digit growth in Infusion driven by BD Alaris that was partially offset by capital seasonality and the prior-year comparisons in Dispensing Solutions and Pharmacy Automation.
• PI (Peripheral Intervention) performance reflects strong growth in the Peripheral Vascular Disease and End Stage Kidney Disease portfolios that was partially offset by the expected impact of volume-based procurement in China, primarily in our Oncology business.
• DS (Diagnostic Solutions) performance reflects strength in BD Kiestra Lab Automation and BD MAX IVD that was partially offset by the delayed start to the U.S. respiratory season.

Risks

• Macroeconomic conditions and their impact on healthcare spending.
• Geopolitical developments such as the situations in Russia and Ukraine, the Middle East and Asia.
• Competitive factors including technological advances and new products introduced by competitors.
• Product efficacy or safety concerns or non-compliance with applicable regulatory requirements.
• Changes to legislation or regulations impacting the healthcare systems.
• Information and technology system disruptions, breaches or breakdowns, including through cyberattacks.
• Increased labor costs and labor shortages or disputes.
• Suppliers' ability to provide products needed for operations.
• Adverse changes in regional, national or foreign economic conditions.
• Risks relating to overall indebtedness.
• Possible impact of public health crises on business and the global healthcare system.
• Interruptions in manufacturing or sterilization processes.
• Pricing and market pressures.
• Difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products.
• Uncertainties of litigation, investigations, subpoenas, settlements, fines, penalties and/or other sanctions.
• Risks associated with the impact, timing or terms of the contemplated separation of BD's Biosciences and Diagnostic Solutions business.

Future Outlook

BD has increased its FY25 adjusted diluted EPS guidance and is pursuing the separation of its Biosciences and Diagnostic Solutions business, expecting to unlock significant value for shareholders. New BD will focus on high-impact R&D and disciplined capital allocation, while Biosciences and Diagnostic Solutions will benefit from enhanced focus and investments as a pure-play Life Sciences Tools and Diagnostics leader.

Management Comments

• 'We delivered strong operational performance in Q1, with revenue growth, margin expansion and earnings per share all ahead of our expectations,' said Tom Polen, chairman, CEO and president of BD.
• 'We continue to transform our company through BD 2025, and our intention to separate Biosciences and Diagnostic Solutions builds on the strong foundation and momentum of our strategy,' said Tom Polen.
• 'This separation is designed to unlock significant value for both New BD and Biosciences and Diagnostic Solutions as each focuses on maximizing growth, delivering leading innovation and operational excellence in their respective markets,' said Tom Polen.

Industry Context

The separation of BD's Biosciences and Diagnostic Solutions business reflects a broader trend in the medical technology industry towards greater specialization and focus. Companies are increasingly looking to streamline their operations and concentrate on areas where they have a competitive advantage. This move allows BD to create a more focused MedTech leader and a differentiated Life Sciences Tools and Diagnostics company, potentially leading to enhanced growth and value creation.

Comparison to Industry Standards

• BD's revenue growth of 9.8% in Q1 fiscal 2025 is strong compared to other large medical technology companies, such as Medtronic and Johnson & Johnson, which have recently reported revenue growth in the mid-single digits.
• The planned separation of Biosciences and Diagnostic Solutions is similar to moves made by other diversified healthcare companies, such as Siemens Healthineers' spin-off from Siemens, to unlock value and enhance focus.
• BD's adjusted diluted EPS growth of 28.0% is significantly higher than the average EPS growth rate for the medical technology industry, indicating strong operational performance.
• The expected adjusted EBITDA margins of approximately 30% for Biosciences and Diagnostic Solutions are competitive with other pure-play life sciences tools and diagnostics companies, such as Thermo Fisher Scientific and Danaher.

Stakeholder Impact

• Shareholders are expected to benefit from the increased value created by the separation of the Biosciences and Diagnostic Solutions business.
• Employees of both New BD and Biosciences and Diagnostic Solutions may experience changes in their roles and responsibilities as a result of the separation.
• Customers of both New BD and Biosciences and Diagnostic Solutions can expect continued innovation and improved service as a result of the increased focus of each entity.
• Suppliers of both New BD and Biosciences and Diagnostic Solutions may experience changes in their relationships with the companies as a result of the separation.

Next Steps

• BD will announce more specifics on the separation plans by the end of fiscal 2025.
• The company intends to target completion of the separation transaction in fiscal 2026.
• BD will remain focused on execution and continue to operate the Biosciences and Diagnostic Solutions business and the other BD businesses in alignment with its BD 2025 strategy.

Key Dates